Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of
this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with
chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma
patients.